Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial

Benzinga2021-11-24

Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection. The temporary pause ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

SC2021
2021-11-25
SC2021
Meek
- SC2021:
  Ok
EHG
2021-11-25
EHG
Like
james33738
2021-11-25
james33738
Yes
WangWang99
2021-11-25
WangWang99
K
- james33738:
  Ok
3eb0d2e3
2021-11-25
3eb0d2e3
Ok
- T2C:
  Yes
- 3eb0d2e3:
  ok
419eae9a
2021-11-25
419eae9a
Ok

发表看法

243

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1151417653?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-24 22:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151417653","market":"us","top_or_hot":-1,"title":"Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial","media":"Benzinga","content":"<div>\n<p>Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial\">网页链接</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial","article_id":"1151417653","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151417653","pubTimestamp":1637765751,"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evalu","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学","MRK":"默沙东"},"translate_title":"默沙东基列停止艾滋病毒联合治疗中期试验的注册","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9,"MRK":0.9},"content_text":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after Merck decided to stop the MK-8507 combination HIV trial.\nParticipants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.\nThe Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.\nLenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.\nIslatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":874226961,"gmtCreate":1637795078154,"gmtModify":1637795078388,"author":{"id":"3574796007598692","authorId":"3574796007598692","name":"SC2021","avatar":"https://static.tigerbbs.com/7db1014f5edc3cd0a7562d4262d0a5a5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574796007598692","authorIdStr":"3574796007598692"},"htmlText":"Meek&nbsp;","listText":"Meek&nbsp;","text":"Meek","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874226961","repostId":1151417653,"repostType":4,"repost":{"id":"1151417653","kind":"news","pubTimestamp":1637765751,"share":"https://www.laohu8.com/m/news/1151417653?lang=&edition=full","pubTime":"2021-11-24 22:55","market":"us","language":"en","title":"Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1151417653","media":"Benzinga","summary":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evalu","content":"<p><b>Gilead Sciences Inc</b>&nbsp;and&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;have&nbsp;temporarily paused enrollment&nbsp;in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.</p>\n<ul>\n <li>The temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after&nbsp;Merck decided to stop the MK-8507 combination HIV trial.</li>\n <li>Participants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.</li>\n <li>The Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.</li>\n <li>Lenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.</li>\n <li>Islatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","GILD":"吉利德科学"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151417653","content_text":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after Merck decided to stop the MK-8507 combination HIV trial.\nParticipants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.\nThe Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.\nLenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.\nIslatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6712261,"gmtCreate":1637795088493,"gmtModify":1637795088575,"authorId":3574796007598692,"author":{"id":3574796007598692,"idStr":"3574796007598692","authorId":3574796007598692,"name":"SC2021","avatar":"https://static.tigerbbs.com/7db1014f5edc3cd0a7562d4262d0a5a5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874226961,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":874265046,"gmtCreate":1637794196321,"gmtModify":1637794196615,"author":{"id":"3586941861951066","authorId":"3586941861951066","name":"EHG","avatar":"https://static.tigerbbs.com/28e4734e50f795c3218330cbb6c3e9a0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586941861951066","authorIdStr":"3586941861951066"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874265046","repostId":1151417653,"repostType":4,"repost":{"id":"1151417653","kind":"news","pubTimestamp":1637765751,"share":"https://www.laohu8.com/m/news/1151417653?lang=&edition=full","pubTime":"2021-11-24 22:55","market":"us","language":"en","title":"Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1151417653","media":"Benzinga","summary":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evalu","content":"<p><b>Gilead Sciences Inc</b>&nbsp;and&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;have&nbsp;temporarily paused enrollment&nbsp;in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.</p>\n<ul>\n <li>The temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after&nbsp;Merck decided to stop the MK-8507 combination HIV trial.</li>\n <li>Participants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.</li>\n <li>The Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.</li>\n <li>Lenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.</li>\n <li>Islatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","GILD":"吉利德科学"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151417653","content_text":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after Merck decided to stop the MK-8507 combination HIV trial.\nParticipants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.\nThe Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.\nLenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.\nIslatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874269994,"gmtCreate":1637793530865,"gmtModify":1637793531093,"author":{"id":"3575544839686991","authorId":"3575544839686991","name":"james33738","avatar":"https://static.tigerbbs.com/e76f4a02d378ba161c6666637ecbba14","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3575544839686991","authorIdStr":"3575544839686991"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874269994","repostId":1151417653,"repostType":4,"repost":{"id":"1151417653","kind":"news","pubTimestamp":1637765751,"share":"https://www.laohu8.com/m/news/1151417653?lang=&edition=full","pubTime":"2021-11-24 22:55","market":"us","language":"en","title":"Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1151417653","media":"Benzinga","summary":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evalu","content":"<p><b>Gilead Sciences Inc</b>&nbsp;and&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;have&nbsp;temporarily paused enrollment&nbsp;in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.</p>\n<ul>\n <li>The temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after&nbsp;Merck decided to stop the MK-8507 combination HIV trial.</li>\n <li>Participants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.</li>\n <li>The Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.</li>\n <li>Lenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.</li>\n <li>Islatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","GILD":"吉利德科学"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151417653","content_text":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after Merck decided to stop the MK-8507 combination HIV trial.\nParticipants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.\nThe Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.\nLenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.\nIslatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":874283953,"gmtCreate":1637792257530,"gmtModify":1637792257735,"author":{"id":"3571302014333483","authorId":"3571302014333483","name":"WangWang99","avatar":"https://static.tigerbbs.com/fd291ad34521fc1ebab496105c2f882d","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3571302014333483","authorIdStr":"3571302014333483"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/874283953","repostId":1151417653,"repostType":4,"repost":{"id":"1151417653","kind":"news","pubTimestamp":1637765751,"share":"https://www.laohu8.com/m/news/1151417653?lang=&edition=full","pubTime":"2021-11-24 22:55","market":"us","language":"en","title":"Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1151417653","media":"Benzinga","summary":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evalu","content":"<p><b>Gilead Sciences Inc</b>&nbsp;and&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;have&nbsp;temporarily paused enrollment&nbsp;in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.</p>\n<ul>\n <li>The temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after&nbsp;Merck decided to stop the MK-8507 combination HIV trial.</li>\n <li>Participants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.</li>\n <li>The Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.</li>\n <li>Lenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.</li>\n <li>Islatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","GILD":"吉利德科学"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151417653","content_text":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after Merck decided to stop the MK-8507 combination HIV trial.\nParticipants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.\nThe Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.\nLenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.\nIslatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6711879,"gmtCreate":1637793536089,"gmtModify":1637793536120,"authorId":3575544839686991,"author":{"id":3575544839686991,"idStr":"3575544839686991","authorId":3575544839686991,"name":"james33738","avatar":"https://static.tigerbbs.com/e76f4a02d378ba161c6666637ecbba14","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874283953,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"}],"langContent":"CN"},{"id":874212576,"gmtCreate":1637791380702,"gmtModify":1637791380835,"author":{"id":"3583621807888930","authorId":"3583621807888930","name":"3eb0d2e3","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583621807888930","authorIdStr":"3583621807888930"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/874212576","repostId":1151417653,"repostType":4,"repost":{"id":"1151417653","kind":"news","pubTimestamp":1637765751,"share":"https://www.laohu8.com/m/news/1151417653?lang=&edition=full","pubTime":"2021-11-24 22:55","market":"us","language":"en","title":"Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1151417653","media":"Benzinga","summary":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evalu","content":"<p><b>Gilead Sciences Inc</b>&nbsp;and&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;have&nbsp;temporarily paused enrollment&nbsp;in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.</p>\n<ul>\n <li>The temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after&nbsp;Merck decided to stop the MK-8507 combination HIV trial.</li>\n <li>Participants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.</li>\n <li>The Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.</li>\n <li>Lenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.</li>\n <li>Islatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","GILD":"吉利德科学"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151417653","content_text":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after Merck decided to stop the MK-8507 combination HIV trial.\nParticipants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.\nThe Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.\nLenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.\nIslatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6711482,"gmtCreate":1637791751046,"gmtModify":1637791751077,"authorId":3576917742134919,"author":{"id":3576917742134919,"idStr":"3576917742134919","authorId":3576917742134919,"name":"T2C","avatar":"https://static.tigerbbs.com/18720cb4368721ede0a87e57a36d26df","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874212576,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"},{"id":6711424,"gmtCreate":1637791390426,"gmtModify":1637791390506,"authorId":3583621807888930,"author":{"id":3583621807888930,"idStr":"3583621807888930","authorId":3583621807888930,"name":"3eb0d2e3","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":874212576,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":874212203,"gmtCreate":1637791334683,"gmtModify":1637791334769,"author":{"id":"3583487187442003","authorId":"3583487187442003","name":"419eae9a","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3583487187442003","authorIdStr":"3583487187442003"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874212203","repostId":1151417653,"repostType":4,"repost":{"id":"1151417653","kind":"news","pubTimestamp":1637765751,"share":"https://www.laohu8.com/m/news/1151417653?lang=&edition=full","pubTime":"2021-11-24 22:55","market":"us","language":"en","title":"Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1151417653","media":"Benzinga","summary":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evalu","content":"<p><b>Gilead Sciences Inc</b>&nbsp;and&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;have&nbsp;temporarily paused enrollment&nbsp;in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.</p>\n<ul>\n <li>The temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after&nbsp;Merck decided to stop the MK-8507 combination HIV trial.</li>\n <li>Participants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.</li>\n <li>The Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.</li>\n <li>Lenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.</li>\n <li>Islatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead, Merck Stop Enrollment In Mid-Stage HIV Combination Therapy Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-24 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","GILD":"吉利德科学"},"source_url":"https://www.benzinga.com/general/biotech/21/11/24270813/gilead-merck-stop-enrollment-in-mid-stage-hiv-combination-therapy-trial","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151417653","content_text":"Gilead Sciences Inc and Merck & Co Inc have temporarily paused enrollment in the Phase 2 study evaluating the combination regimen of islatravir and lenacapavir in HIV infection.\n\nThe temporary pause has been implemented out of an abundance of caution to allow the companies to consider potential protocol adjustments to the trial after Merck decided to stop the MK-8507 combination HIV trial.\nParticipants enrolled in this trial will continue to receive the study drug and be monitored per the current protocol.\nThe Phase 2 study is designed to evaluate the safety and antiviral effect of an oral weekly regimen of islatravir in combination with lenacapavir in virologically suppressed people aged 18 years and older with HIV.\nLenacapavir is Gilead’s investigational long-acting HIV-1 capsid inhibitor.\nIslatravir (MK-8591) is Merck’s investigational nucleoside reverse transcriptase translocation inhibitor under evaluation in more than ten clinical trials.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":243,"commentSize":24,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151417653"}